CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin”
CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference”
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its abstract was selected for in-person poster presentation at the 2023 SNO/ASCO CNS Cancer Conference taking place in San Francisco from Aug. 10-12, … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference”
A simple search of the Internet shows a number of clinical trials attempting to improve treatment options for glioblastoma (“GBM”) brain cancers, and Congress will recognize a National Glioblastoma Awareness Day next month to further support development of effective brain cancer responses. That’s because, as the U.S. Social Security Administration acknowledges in its protocols for … Continue reading “National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in the Virtual Investor Summer Spotlight Series. Company CEO John Climaco and chief medical officer Sandra L. Silberman will both be participating on a live webcast … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in an upcoming webcast fireside chat. The company announced that CEO John Climaco will present at the Healthcare Virtual Conference Part II; the event is presented … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference”
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study”
